Capricor Therapeutics, Inc. (CAPR) P/E Ratio History
Deep ValueTrading at -13.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2018–2018
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Capricor Therapeutics, Inc. (CAPR) trades at a price-to-earnings ratio of -13.0x, with a stock price of $29.34 and trailing twelve-month earnings per share of $-2.00.
The current P/E is 107% below its 5-year average of 183.6x. Over the past five years, CAPR's P/E has ranged from a low of 60.9x to a high of 340.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CAPR trades at a 159% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, CAPR trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CAPR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CAPR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CAPR P/E vs Peers
Cell and Gene Therapy Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $13B | 18.5Lowest | 0.36Best | +58%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CAPR Historical P/E Data (2018–2018)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2018 Q3 | Sep 30 2018 | $10.50 | $0.07 | 150.0x | -18% |
| FY2018 Q2 | Jun 30 2018 | $13.40 | $0.22 | 60.9x | -67% |
| FY2018 Q1 | Mar 31 2018 | $13.60 | $0.04 | 340.0x | +85% |
Average P/E for displayed period: 183.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CAPR — Frequently Asked Questions
Quick answers to the most common questions about buying CAPR stock.
What is CAPR's P/E ratio?
Capricor Therapeutics, Inc. (CAPR) trailing twelve-month P/E ratio is -13.0x, based on TTM diluted EPS of $-2.00. The 5-year average P/E is 183.6x and the historical range spans 60.9x to 340.0x.
Is CAPR stock overvalued or undervalued?
CAPR trades at -13.0x P/E, below its 5-year average of 183.6x. At the 0th percentile of its historical range (60.9x–340.0x), the stock is priced at a discount to its own history.
Is CAPR stock expensive?
No, CAPR is not expensive on a historical basis. The current P/E of -13.0x is below the 5-year average of 183.6x and sits at the 0th percentile of its valuation range.
What is CAPR's historical P/E range?
Over the past 5 years, CAPR's P/E ratio has ranged from 60.9x to 340.0x, with a median of 150.0x and an average of 183.6x. The current P/E of -13.0x places the stock at the 0th percentile of this range. Full historical data spans 2018–2018.
How does CAPR's P/E compare to the S&P 500?
CAPR trades at -13.0x P/E versus the S&P 500 median of 24.3x. The 153% discount to the market suggests lower growth expectations or perceived higher risk.
How does CAPR's valuation compare to Healthcare peers?
Capricor Therapeutics, Inc. P/E of -13.0x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CAPR's PEG ratio?
CAPR PEG ratio is N/A, based on a P/E of -13.0x and EPS growth of -96.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CAPR's earnings yield?
CAPR earnings yield is N/A, the inverse of its -13.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.